Your session is about to expire
← Back to Search
Physical Therapy + Medication for Parkinson's Disease (TAME-PD Trial)
Phase < 1
Recruiting
Led By Shnehal Patel
Research Sponsored by Hubert Fernandez
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Punctuation of 5 in Hoehn and Yard modified scale: 'Wheelchair bound or bedridden unless aided'.
Presence of signs and symptoms suggestive of atypical parkinsonism
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.
Who is the study for?
This trial is for Parkinson's disease patients with significant gait and balance issues, despite stable dopaminergic therapy. They must score ≥2 on the UPDRS item for walking impairment. Exclusions include severe mental health issues, epilepsy, heart problems, glaucoma, liver disease, allergies to study drugs, wheelchair dependence or bedridden state without help.
What is being tested?
The TAME-PD trial is testing if adding low doses of either methylphenidate or atomoxetine to physical therapy can improve gait and balance in Parkinson's patients more than physical therapy alone. It's a pilot study where participants are randomly assigned to one of two groups in a blinded fashion.
What are the potential side effects?
Potential side effects from methylphenidate may include nervousness, trouble sleeping and increased blood pressure. Atomoxetine might cause dry mouth, nausea or fatigue. Physical therapy generally has minimal risks but could sometimes result in muscle soreness.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I need help to move from a wheelchair or bed.
Select...
I show signs of unusual Parkinson-like symptoms.
Select...
I don't have severe mental health issues, epilepsy, hyperthyroidism, glaucoma, irregular heartbeat, Tourette syndrome, liver disease, or allergies to specific ADHD medications.
Select...
I cannot undergo physical therapy due to health reasons.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Balance Evaluation
Secondary study objectives
Change in gait
Other study objectives
Motor function
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: Physical TherapyActive Control1 Intervention
Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
Group II: Physical Therapy plus MethylphenidateActive Control2 Interventions
Methylphenidate 20 mg daily in combination with PT
Group III: Physical Therapy plus AtomoxetineActive Control2 Interventions
Atomoxetine 10 mg daily in combination with PT or PT alone.
Find a Location
Who is running the clinical trial?
Hubert FernandezLead Sponsor
Shnehal PatelPrincipal InvestigatorThe Cleveland Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I don't have conditions that majorly affect my walking or balance.I need help to move from a wheelchair or bed.I show signs of unusual Parkinson-like symptoms.I don't have severe mental health issues, epilepsy, hyperthyroidism, glaucoma, irregular heartbeat, Tourette syndrome, liver disease, or allergies to specific ADHD medications.I have Parkinson's with major walking issues despite medication, not expected to change my meds soon.I cannot undergo physical therapy due to health reasons.I am not currently using, nor have I used MAO inhibitors in the last two weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Physical Therapy
- Group 2: Physical Therapy plus Methylphenidate
- Group 3: Physical Therapy plus Atomoxetine
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.